Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 4,115 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $88.39, for a total transaction of $363,724.85. Following the sale, the chief executive officer now directly owns 140 shares in the company, valued at approximately $12,375. The transaction was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics (NASDAQ:UTHR) traded up 2.26% on Friday, hitting $91.79. The stock had a trading volume of 571,332 shares. United Therapeutics has a 52-week low of $70.34 and a 52-week high of $116.65. The stock has a 50-day moving average of $90.90 and a 200-day moving average of $95.98. The company has a market cap of $4.339 billion and a P/E ratio of 17.34.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.

UTHR has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. United Therapeutics currently has a consensus rating of “Buy” and an average price target of $102.21.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.